Blueprint Medicines Stock Price. Everything You Need To Know About The Blueprint Medicines Stock!
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 641 full-time employees. The company went IPO on 2015-04-30. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). The company is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Blueprint Medicines Stock Price. Everything You Need To Know About The Blueprint Medicines Stock! performance
- Employees 641
- Company HQ Cambridge
- Website https://www.blueprintmedicines.com/
- BPMC Asset Type Common Stock
- BPMC Market Capitalization 5.8B
- Earnings Per Share -8.37
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you looking to invest in Blueprint Medicines from Malaysia, Thailand, Indonesia, or Vietnam? Look no further, as Zorion has got you covered! Blueprint Medicines is a cutting-edge biopharmaceutical company focused on delivering targeted therapies for patients with genomically defined diseases. With their expertise, Blueprint Medicines is at the forefront of precision medicine. Investing in this stock can be a wise choice for those seeking long-term growth and profitability. With Zorion’s comprehensive investment insights and recommendations, retail investors from Malaysia, Thailand, Indonesia, and Vietnam can make informed decisions. Access educational resources and enhance your investment knowledge to maximize potential returns. Start investing in Blueprint Medicines today and let Zorion be your trusted investment platform.
